Platelet Ratio Linked to HFpEF Survival
Researchers find higher platelet-to-white blood cell ratios are associated with lower mortality in critical heart failure patients.
Updated on Oct. 21, 2026 in Heart Disease
Live Poll
Should medical practitioners prioritize using existing routine blood tests to assess patient risk?
A study published on October 21, 2026, identifies a correlation between increased platelet-to-white blood cell ratios and improved 28-day survival rates in critically ill patients with heart failure with preserved ejection fraction (HFpEF). Researchers utilized machine learning to analyze thousands of ICU admissions to determine these prognostic indicators.
Why it matters
This metric potentially clarifies the interplay between leukocyte-driven inflammatory stress and platelet availability in heart failure. Understanding this balance may help clinicians better assess mortality risk in the intensive care unit.
The analysis of 5,774 patients showed a 10.95% mortality rate over 28 days, with the machine-learning model achieving an AUROC of 0.813. Hazard ratios for mortality in the second, third, and fourth quartiles were 0.79, 0.58, and 0.61, respectively.
The details
The research integrated clinical data from the MIMIC-IV and eICU databases to evaluate the prognostic value of blood count ratios using Kaplan-Meier curves and Cox models. Results indicate that while adding this nonlinear data to baseline models improves predictive capabilities, its overall impact on standard clinical assessment remains incremental.
Timeline
24 hours after ICU admission is when the first blood measurements were recorded.
28 days marks the total duration of the all-cause mortality observation period.
Health Landscape
This study follows a pattern established by the MIMIC-IV and eICU clinical database research programs for evaluating patient outcomes. It demonstrates how machine learning is increasingly utilized to parse large-scale electronic health records for new prognostic markers in cardiology.
Patients and caregivers may benefit from more accurate clinical risk assessments during critical care stays. These findings do not alter immediate bedside treatment protocols but contribute to the ongoing refinement of prognostic monitoring in heart failure.
The takeaway
This analysis highlights how hematological ratios can serve as a diagnostic tool to help medical staff predict outcomes in the ICU. Future clinical application will depend on validating these specific ratios across more diverse patient populations.
Further reading
For broader insights on cardiovascular clinical research, visit the Heart Disease section.
Source note: This article includes information reported by Nature.
Live Poll
Should medical practitioners prioritize using existing routine blood tests to assess patient risk?
